Investigating Participation Patterns Among Stage IV Melanoma Patients
Not yet recruiting
- Conditions
- Stage IV Melanoma
- Registration Number
- NCT06093594
- Lead Sponsor
- Power Life Sciences Inc.
- Brief Summary
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation.
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Aged ≥ 18 years old
- Diagnosis of stage IV melanoma
- Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion Criteria
- Female patients who are currently pregnant or nursing
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Inability to perform regular electronic reporting
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of stage IV melanoma patients who remain in clinical trial to trial completion 12 months Number of stage IV melanoma patients who decide to enroll in a clinical research 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Power Life Sciences
🇺🇸San Francisco, California, United States